Quotient Amersham Radiochemicals rebrands to Quotient Custom Radiolabelling

The company’s decision follows two years of expansion and investment in a £15m laboratory in Cardiff.

Quotient Bioresearch, a provider of early stage drug development services to pharmaceutical and biotechnology clients worldwide, has acquired Quotient Amersham Radiochemicals from GE Healthcare in 2009.

Quotient Bioresearch Chemistry and Metabolism MD Stephen Lewinton said the past two years have been particularly exciting for Quotient and it’s with accomplishment that they officially change name to Quotient Custom Radiolabelling.

"We inherited an enviable legacy from Amersham Radiolabeling Services and through our investment in the business and in the new facility, we’re able to provide a fully-integrated quick response service for our customers," Lewinton said.